Elisabetta Bugianesi is a practising hepatologist based at the Gastroenterology Division of the University Hospital ‘Città della Salute e della Scienza’ in Turin, Italy. She is Head of the Gastrohepatology Laboratory and the Lead Physician for the Hepatology Outpatient Clinic (with approximately 1500 patients/year). Professor Bugianesi has over 15 years of experience in the field of non-alcoholic fatty liver disease (NAFLD) as a clinical researcher.
Professor Bugianesi’s work has made a particular impact in describing metabolic mechanisms of insulin resistance related to the onset and progression of liver damage. She has driven research on the natural history of NAFLD (including the first demonstration of hepatocellular carcinoma as a complication of non-alcoholic steatohepatitis-related liver disease) and the development of non-invasive markers of fibrosis, including the NAFLD fibrosis score. Professor Bugianesi was Principal Investigator of the Seventh Framework Programme (FP7)-funded Fatty Liver: Inhibition of Progression (FLIP) consortium and is currently Principal Investigator in two other major research consortia: Elucidating Pathways of Steatohepatitis (EPoS) and Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS).
Professor Bugianesi is a member of the Lancet-EASL Commission for Liver Disease in Europe and Associate Editor of the Journal of Hepatology.